who discovered glp-1 agonists The Discovery of Glucagon-Like Peptide 1 (GLP-1) LY3437943, a novel triple glucagon,
Description
The rise of the incretin therapies for obesity has attracted tremendous interest, both from drug developers and prospective patients (consumers)
2007, Pujadas et al
But heres the truth: Your body is unique, and thats not a flaw
In addition, its use has been associated with pancreatitis, gallbladder disease, acute kidney injury, heart rate increases, and suicidal thoughts
OGTT, oral glucose tolerance test
Therapeutic innovation now includes dual and triple incretin receptor agonists [4,5,6,7] as well as orally bioavailable small-molecule formulations [8, 9], reflecting ongoing efforts to enhance pharmacodynamic durability
